HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.

AbstractBACKGROUND:
Mitochondrial dysfunction is increasingly recognized as an important feature of multiple sclerosis (MS) pathology and may be relevant for clinical disease progression. However, it is unknown whether mitochondrial DNA (mtDNA) levels in the cerebrospinal fluid (CSF) associate with disease progression and therapeutic response.
OBJECTIVES:
To evaluate whether CSF concentrations of mtDNA in MS patients can serve as a marker of ongoing neuropathology and may be helpful to differentiate between MS disease subtypes. To explore the effect of disease-modifying therapies on mtDNA levels in the CSF.
METHODS:
CSF mtDNA was measured using a digital polymerase chain reaction (PCR) CSF mtDNA in two independent MS cohorts. The cohorts included 92 relapsing-remitting multiple sclerosis (RRMS) patients, 40 progressive multiple sclerosis (PMS) patients (27 secondary progressive and 13 primary progressive), 50 various neurologic disease controls, and 5 healthy controls.
RESULTS:
Patients with PMS showed a significant increase in CSF mtDNA compared to non-inflammatory neurologic disease controls. Patients with higher T2 lesion volumes and lower normalized brain volumes showed increased concentration of mtDNA. Patients treated with fingolimod had significantly lower mtDNA copy levels at follow-up compared to baseline.
CONCLUSION:
Our results showed a non-specific elevation of concentration of mtDNA in PMS patients. mtDNA concentrations respond to fingolimod and may be used to monitor biological effect of this treatment.
AuthorsCyra E Leurs, Petar Podlesniy, Ramon Trullas, Lisanne Balk, Martijn D Steenwijk, Arjan Malekzadeh, Fredrik Piehl, Bernard Mj Uitdehaag, Joep Killestein, Jack van Horssen, C E Teunissen
JournalMultiple sclerosis (Houndmills, Basingstoke, England) (Mult Scler) Vol. 24 Issue 4 Pg. 472-480 (04 2018) ISSN: 1477-0970 [Electronic] England
PMID28294696 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers
  • DNA, Mitochondrial
Topics
  • Adult
  • Biomarkers (cerebrospinal fluid)
  • DNA, Mitochondrial (cerebrospinal fluid)
  • Disease Progression
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mitochondria (metabolism)
  • Multiple Sclerosis (cerebrospinal fluid, drug therapy, pathology)
  • Multiple Sclerosis, Chronic Progressive (cerebrospinal fluid)
  • Multiple Sclerosis, Relapsing-Remitting (cerebrospinal fluid)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: